Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: Clinical and immunologic findings

Journal of Clinical Oncology

Volumn 20, Issue 20, 2002, Pages 4169-4180

  Belli, Filiberto ^a   Testori, Alessandro ^a   Rivoltini, Licia ^a   Maio, Michele ^a   Andreola, Giovanna ^a   Sertoli, Mario Roberto ^a   Gallino, Gianfrancesco ^a   Piris, Adriano ^a   Cattelan, Alessandro ^a   Lazzari, Ivano ^a   Carrabba, Matteo ^a   Scita, Giorgio ^a   Santantonio, Cristina ^a   Pilla, Lorenzo ^a   Tragni, Gabrina ^a   Lombardo, Claudia ^a   Arienti, Flavio ^a   Marchianò, Alfonso ^a   Queirolo, Paola ^a   Bertolini, Francesco ^a   Cova, Agata ^a   Lamaj, Elda ^a   Ascani, Lucio ^a   Camerini, Roberto ^a   Corsi, Marco ^a   Cascinelli, Natale ^a   Lewis, Jonathan J ^a   Srivastava, Pramod ^a   Parmiani, Giorgio ^a   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GLYCOPROTEIN GP 96; HEAT SHOCK PROTEIN; HLA ANTIGEN CLASS 1; INTERLEUKIN 2; MELANOMA ANTIGEN; ONCOPHAGE; PEPTIDE DERIVATIVE; TUMOR VACCINE;

ADULT; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; METASTASIS; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; FEMALE; HEAT-SHOCK PROTEINS; HLA ANTIGENS; HUMANS; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; REMISSION INDUCTION; SKIN NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 0037108696     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.09.134     Document Type: Article

References (33)

1. Legha SS, Ring S, Eton O. et al: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16:1752-1759, 1999
2. Eton O, Legha SS, Bedikian AY, et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 20:2045-2052, 2002
3. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17:968-975, 1999
4. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332, 1998
5. Marchand M, Van Baren N, Weynants P, et al: Tumor regression observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219-230, 1999
6. Thurner B, Haendle I, Roder C, et al: Vaccination with Mage-3A1 peptide-pulsed mature monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-1678, 1999
7. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327, 1998
8. Parmiani G, Rodolfo M, Melani C: Immunological gene therapy with ex vivo gene-modified tumor cells: A critique and a reappraisal. Hum Gene Ther 11:1269-1275, 2000
9. Cormier JN, Salgaller ML, Prevette T, et al: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART1/Melan-A. Cancer J Sci Am 3:37-44, 1996
10. Srivastava PK: Interaction of heat shock proteins with peptides and with antigen presenting cells: Chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20:395-425, 2002
11. Suto R, Srivastava PK: A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269:1585-1588, 1996
12. Ishii T, Udono H, Yamano T, et al: Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol 162:1303-1309, 1999
13. Castelli C, Ciupitu A-MT, Rini F, et al: Human HSP70 peptide complexes specifically activate anti-melanoma T-cells. Cancer Res 61:222-227, 2001
14. Tamura Y, Peng P, Liu K, et al: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117-120, 1997
15. Robert J, Menoret A, Basu S, Cohen N, Srivastava PK: Phylogenetic conservation of the molecular and immunological properties of the chaperones gp96 and hsp70. Eur J Immunol 31:186-95, 2001
16. Janetzki S, Palla D, Rosenhauer V, et al: Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: A pilot study. Int J Cancer 88:232-238, 2000
17. Srivastava PK: Do human cancers express shared protective antigens? or the necessity of remembrance of things past. Semin Immunol 8:295-302, 1996
18. Srivastava PK, Jaikaria NS. Methods of purification of heat shock protein-peptide complexes for use as vaccines against cancers and infectious diseases. Methods Mol Biol 156:175-186, 2001
19. Pass HA, Schwarz SL, Wunderlick JR, Rosenberg SA: Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay. Cancer J Sci Am 4:316-323, 1998
20. Lewis JJ, Janetzki S, Schaed S, et al: Evaluation of CD8+ T-cell frequencies by the ELISPOT assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer 87:391-398. 2000
21. Scheibenbogen C, Romero P, Rivoltini L, et al: Quantification of antigen-reactive T cells in peripheral blood by IFNγ-ELISPOT and chromium release assay: A four centre comparative trial. J Immunol Methods 244:81-89, 2000
22. Kawakami Y, Eliyahu S, Delgado CH, et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 91:3515-3519, 1994
23. Mazzocchi A, Storkus WJ, Traversari C, et al: Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. J Immunol 157:3030-3038, 1996
24. Clarke WH Jr, Elder DE, Guerry D IV, et al: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-1904, 1989
25. Mihm MC Jr, Clemente CG, Cascinelli N: Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74:43-47, 1996
26. Castellino F, Boucher PE, Eichelberg K, et al: Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 191:1957-1964, 2000
27. Singh-Jasuja H, Toes RE, Spee P, et al: Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med 191:1965-1974, 2000
28. Pende D, Accame L, Pareti L, et al: The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur J Immunol 28:2384-2394, 1998
29. Meng S-D, Gao T, Gao GF, Tien P: HBV-specific peptide associated with heat-shock protein gp96. Lancet 357:528-529, 2001
30. Nagorsen D, Keilholz U, Rivoltini L, et al: Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecules, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res 60:4850-4854, 2000
31. Romero P, Dunbar PR, Valmori D, et al: Ex-vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188:1641-1650, 1998
32. Anichini A, Molla A, Mortarini R, et al: An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 190:651-667, 1999
33. Ferrone S, Marincola FM: Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487-494, 1995